JP2021519289A5 - - Google Patents

Info

Publication number
JP2021519289A5
JP2021519289A5 JP2020551503A JP2020551503A JP2021519289A5 JP 2021519289 A5 JP2021519289 A5 JP 2021519289A5 JP 2020551503 A JP2020551503 A JP 2020551503A JP 2020551503 A JP2020551503 A JP 2020551503A JP 2021519289 A5 JP2021519289 A5 JP 2021519289A5
Authority
JP
Japan
Prior art keywords
cell
cells
cancer
cytotoxic
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020551503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519289A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/024111 external-priority patent/WO2019191125A1/en
Publication of JP2021519289A publication Critical patent/JP2021519289A/ja
Publication of JP2021519289A5 publication Critical patent/JP2021519289A5/ja
Priority to JP2023216572A priority Critical patent/JP2024045111A/ja
Pending legal-status Critical Current

Links

JP2020551503A 2018-03-27 2019-03-26 ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法 Pending JP2021519289A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023216572A JP2024045111A (ja) 2018-03-27 2023-12-22 ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862648888P 2018-03-27 2018-03-27
US201862648880P 2018-03-27 2018-03-27
US62/648,888 2018-03-27
US62/648,880 2018-03-27
PCT/US2019/024111 WO2019191125A1 (en) 2018-03-27 2019-03-26 Methods of making and using guidance and navigation control proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023216572A Division JP2024045111A (ja) 2018-03-27 2023-12-22 ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法

Publications (2)

Publication Number Publication Date
JP2021519289A JP2021519289A (ja) 2021-08-10
JP2021519289A5 true JP2021519289A5 (cg-RX-API-DMAC7.html) 2022-05-11

Family

ID=68060498

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020551503A Pending JP2021519289A (ja) 2018-03-27 2019-03-26 ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法
JP2020551549A Active JP7573441B2 (ja) 2018-03-27 2019-03-26 ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
JP2023216572A Pending JP2024045111A (ja) 2018-03-27 2023-12-22 ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法
JP2024180215A Active JP7781243B2 (ja) 2018-03-27 2024-10-15 ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020551549A Active JP7573441B2 (ja) 2018-03-27 2019-03-26 ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
JP2023216572A Pending JP2024045111A (ja) 2018-03-27 2023-12-22 ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法
JP2024180215A Active JP7781243B2 (ja) 2018-03-27 2024-10-15 ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法

Country Status (11)

Country Link
US (2) US12029761B2 (cg-RX-API-DMAC7.html)
EP (2) EP3773621A4 (cg-RX-API-DMAC7.html)
JP (4) JP2021519289A (cg-RX-API-DMAC7.html)
KR (2) KR20200135935A (cg-RX-API-DMAC7.html)
CN (5) CN111527108A (cg-RX-API-DMAC7.html)
AU (4) AU2019243453B2 (cg-RX-API-DMAC7.html)
CA (2) CA3094997A1 (cg-RX-API-DMAC7.html)
IL (4) IL312224B2 (cg-RX-API-DMAC7.html)
SG (2) SG11202008474QA (cg-RX-API-DMAC7.html)
TW (2) TW201945013A (cg-RX-API-DMAC7.html)
WO (2) WO2019191125A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11787863B2 (en) * 2017-06-25 2023-10-17 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
EP3645741A4 (en) * 2017-06-25 2021-08-25 Systimmune, Inc. ANTI-4-1BB ANTIBODIES AND METHOD OF MANUFACTURING AND USING
US20260008861A9 (en) * 2017-06-25 2026-01-08 Systimmune, Inc. Anti-4-1bb antibodies and methods of making and using thereof
SG11201912865VA (en) * 2017-06-25 2020-01-30 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
JP7383605B2 (ja) * 2017-06-25 2023-11-20 システィミューン, インク. 抗pd-l1抗体とその作製及び使用方法
TW201904588A (zh) * 2017-06-25 2019-02-01 美商西雅圖免疫公司 引導及導航控制蛋白質之製造及使用方法
EP3773621A4 (en) * 2018-03-27 2022-03-23 Systimmune, Inc. GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE
CN118580364A (zh) * 2019-11-06 2024-09-03 西雅图免疫公司 制导和导航控制蛋白及其制备和使用方法
CA3171363A1 (en) * 2019-12-20 2021-06-24 Kisoji Biotechnology Inc. Polypeptides, protein complexes and method for making same
CA3173980A1 (en) * 2020-03-03 2021-09-10 Systimmune, Inc. Anti-cd19 antibodies and methods of using and making thereof
TWI908779B (zh) * 2020-03-17 2025-12-21 美商西雅圖免疫公司 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法
BR112023005152A2 (pt) * 2020-09-21 2023-04-25 Systimmune Inc Anticorpo biespecífico com especificidade intensificada (seba)
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
US20240262930A1 (en) * 2021-05-28 2024-08-08 Xyone Therapeutics Inc. Multi-specific antibody constructs against the muc1-c/extracellular domain (muc1-c/ed)
US12559576B2 (en) 2021-11-11 2026-02-24 Regeneron Pharmaceuticals, Inc. CD20-PD1 binding molecules and methods of use thereof
CN118974091A (zh) * 2022-04-11 2024-11-15 阿斯利康(瑞典)有限公司 T细胞结合蛋白
AU2023254191A1 (en) 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1354600A1 (en) * 2002-04-19 2003-10-22 Affimed Therapeutics AG Antibody combination useful for tumor therapy
US9783601B2 (en) * 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
EP2930188A1 (en) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
MX386342B (es) * 2014-07-25 2025-03-18 Memorial Sloan Kettering Cancer Center Móleculas de unión a her2 y cd3 biespecíficas.
WO2016019969A1 (en) * 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
ES2688035T3 (es) * 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
CN107531784B (zh) 2015-04-29 2021-08-27 生物医学研究所 通过多特异性抗体超强力地中和细胞因子和其用途
WO2017011342A1 (en) * 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
IL304871A (en) * 2016-01-11 2023-10-01 Inhibrx Inc Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses
EP3443006B1 (en) * 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
ES3056995T3 (en) * 2016-04-13 2026-02-25 Vivia Biotech Sl Ex vivo bite-activated t cells
EP4166161B1 (en) * 2016-04-14 2026-03-04 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201808457PA (en) * 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
CN106589129B (zh) 2016-12-30 2021-03-05 上海近岸生物科技有限公司 一种结合cd19、cd3和cd28的三功能分子及其应用
TW201904588A (zh) * 2017-06-25 2019-02-01 美商西雅圖免疫公司 引導及導航控制蛋白質之製造及使用方法
SG11201912865VA (en) * 2017-06-25 2020-01-30 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
US11787863B2 (en) * 2017-06-25 2023-10-17 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
EP3773621A4 (en) * 2018-03-27 2022-03-23 Systimmune, Inc. GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE

Similar Documents

Publication Publication Date Title
Liu et al. Novel strategies for cancer immunotherapy: counter-immunoediting therapy
Liu et al. mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion
Vivier et al. Natural killer cell therapies
Paijens et al. Tumor-infiltrating lymphocytes in the immunotherapy era
Liu et al. Targeting epidermal growth factor‐overexpressing triple‐negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor
Jin et al. CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers
Leong et al. B cells in lung cancer—not just a bystander cell: a literature review
Choi et al. Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice
Mottok et al. Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies
Rotiroti et al. Targeting CD33 in chemoresistant AML patient-derived xenografts by CAR-CIK cells modified with an improved SB transposon system
US20220008464A1 (en) Modified t cell, preparation method therefor and use thereof
Maki et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G
Shiozawa et al. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells
Oh et al. Targeting cyclin D-CDK4/6 sensitizes immune-refractory cancer by blocking the SCP3–NANOG axis
JP2021502330A (ja) Tigitおよび/またはcd112rを標的とするか、またはcd226過剰発現を含む、組成物および免疫治療の方法
Bisig et al. New biomarkers in T-cell lymphomas
Moreno-Lama et al. Coordinated signals from PARP-1 and PARP-2 are required to establish a proper T cell immune response to breast tumors in mice
Ramesh et al. Chimeric antigen receptor T‐cells: Properties, production, and quality control
Zhu et al. CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside
Sim et al. Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development
Adachi et al. Cullin-5 deficiency promotes chimeric antigen receptor T cell effector functions potentially via the modulation of JAK/STAT signaling pathway
Suzuki et al. Activation of STING in pancreatic cancer-associated fibroblasts exerts an antitumor effect by enhancing tumor immunity
Nedelkovska et al. Follicular lymphoma tregs have a distinct transcription profile impacting their migration and retention in the malignant lymph node
Aqaqe et al. An ERG enhancer–based reporter identifies leukemia cells with elevated leukemogenic potential driven by ERG-USP9X feed-forward regulation
Kim et al. Comparison of the different anti-CD16 antibody clones in the activation and expansion of peripheral blood NK cells